Sign in

CIK 0001653087 · Accelerated filer<br>Smaller reporting company

Alector, Inc.

Sign in to watch
Ticker
ALEC
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
operating
EIN
822933343
Phone
415-231-5660
Business address
131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO, CA, 94080
Former names
Alector LLC
  1. 4 Planned sale Director sold 14,000 shares at $2.36 ($32,998)
  2. 4 Derivatives Options or other derivatives
  3. 4 Grant or award President and Head of R&D acquired 54,725 shares (grant or award)
  4. 4 Grant or award Chief Executive Officer acquired 137,125 shares (grant or award)
  5. 3 Insider Initial Statement of Ownership
  6. 3 Insider Initial Statement of Ownership
  7. 4 Planned sale Director sold 1,000 shares at $1.44 ($1,440)
  8. 4 Grant or award Director acquired 28,700 shares (grant or award)
  9. 4 Grant or award Director acquired 28,700 shares (grant or award)
  10. 4 Grant or award Director acquired 28,700 shares (grant or award)
  11. 4 Grant or award Director acquired 28,700 shares (grant or award)
  12. 4 Grant or award Director acquired 28,700 shares (grant or award)
  13. 4 Grant or award Director acquired 28,700 shares (grant or award)
  14. 4 Grant or award Director acquired 28,700 shares (grant or award)
  15. 4 Open-market sale Chief Financial Officer sold 16,488 shares at $1.34 ($22,068)
  16. 4 Open-market sale President and Head of R&D sold 23,890 shares at $1.34 ($31,974)
  17. 4 Open-market sale Chief Executive Officer sold 52,087 shares at $1.34 ($69,713)
  18. 4 Grant or award Director acquired 15,833 shares (grant or award)
  19. 4 Open-market sale President and Head of R&D sold 29,073 shares at $1.47 ($42,662)
  20. 4 Open-market sale Chief Executive Officer sold 40,330 shares at $1.47 ($59,176)

Page 3 of 16 · 301 filings